Table 1. Clinical characteristics of R-CHOP treated patients as a function of MGMT methylation status.
| Total (n = 75) | Unmethylated (n = 60) | Methylated (n = 15) | p-value | |
|---|---|---|---|---|
| Sex | 0.91 | |||
| Men | 39 | 31 | 8 | |
| Women | 36 | 29 | 7 | |
| Extranodal involvement | 0.80 | |||
| Yes | 32 | 25 | 7 | |
| No | 41 | 33 | 8 | |
| Missing | 2 | 2 | 0 | |
| Stage | 0.49 | |||
| I-II | 36 | 30 | 6 | |
| III-IV | 39 | 30 | 9 | |
| Elevated LDH | 0.16 | |||
| Yes | 33 | 24 | 9 | |
| No | 42 | 36 | 6 | |
| B symptoms | 0.12 | |||
| Yes | 31 | 22 | 9 | |
| No | 40 | 36 | 6 | |
| Missing | 2 | 2 | 0 | |
| IPI score | 0.41 | |||
| 0–2 | 54 | 44 | 10 | |
| 3–5 | 21 | 16 | 5 | |
| Performance score* | 0.35 | |||
| Good | 69 | 56 | 13 | |
| Bad | 6 | 4 | 2 | |
| Response | 0.097 | |||
| CR/Cru | 62 | 51 | 11 | |
| PD/PR | 6 | 3 | 3 | |
| Missing/Mors | 7 | 6 | 1 | |
| Age, mean (range) | 60.8 (22–86) | 60.6 years (22–83) | 61.5 years (27–86) | 0.84 |
*Eastern Cooperative Oncology Group.
LDH, lactate dehydrogenase; IPI, international prognostic index; CR, complete response, unconfirmed complete response; PD, progressive disease; PR, partial response.